Needham Initiates Coverage On Neumora Therapeutics with Buy Rating, Announces Price Target of $23
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and sets a price target of $23.

July 22, 2024 | 9:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has initiated coverage on Neumora Therapeutics with a Buy rating and a price target of $23, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $23 by a reputable analyst is likely to generate positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100